查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454250

桥本甲状腺炎治疗药物的全球市场：按药物类型、按特性、按最终用户、按地区

Global Hashimoto's Thyroiditis Drug Market, By Drug Type, By Features, By End User, By Geography .
出版日期: | 出版商: Coherent Market Insights | 英文 192 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球桥本甲状腺炎治疗市值为21.8亿美元，预计2024年至2031年复合年增长率为5.7%，到2031年将达到34亿美元。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 21.8亿美元
实际资料 2019-2023 预测期 2024-2031
预测期间 2023/2024 至 2030/2031 年复合年增长率： 5.70% 2030/2031价值预测 34亿美元
图 1. 2023 年桥本甲状腺炎治疗药物按地区分類的全球市场占有率（%）
全球桥本甲状腺炎药物市场-IMG1

桥本氏甲状腺炎，又称为慢性淋巴球性甲状腺炎，是一种甲状腺受到人体免疫系统攻击的长期自体免疫疾病。主要症状包括颈部甲状腺肿、疲劳、不明原因的体重增加和对寒冷敏感。甲状腺机能低下症是美国甲状腺功能减退症最常见的原因之一，影响约 1,400 万美国，每年花费数十亿美元的治疗费用。有多种药物可用于治疗甲状腺机能低下症，包括替代甲状腺激素的左旋甲状腺素、抑制免疫反应的皮质类固醇以及其他症状管理药物。由于发病率和整体医疗费用的上升，预计桥本甲状腺炎治疗市场在未来几年将显着增长。

市场动态：

桥本的甲状腺炎治疗市场受到全球自体免疫疾病盛行率上升、老年人口增加以及对该疾病及其治疗认识不断提高的推动。根据美国生物技术资讯中心（NCBI）2023年发表的一篇论文，在美国和碘摄取充足的地区，桥本氏症是6岁以后甲状腺机能低下症最常见的原因。在全球范围内，男性发病率估计为每年每 1,000 人 0.8 例，女性每年每 1,000 人发病率为 3.5 例。然而，新兴市场缺乏认识、生物製药成本高和社会耻辱继续抑制市场成长。同时，标靶治疗、联合治疗和线上疾病社群的发展正在为该领域的参与者创造商机。市场越来越多地采用口服药物而不是手术干预。公司正在投资研发，以开发具有更高功效和安全性的新配方。

本研究的主要特点

  • 本报告对全球桥本氏甲状腺炎治疗药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%） 。
  • 它还说明了各个细分市场的潜在收益成长机会，并为该市场提供了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
  • 根据公司亮点、产品系列、主要亮点、业绩和策略等参数列出了全球桥本甲状腺炎治疗药物市场的主要公司概况。
  • 本研究涵盖的主要企业包括艾伯维公司(AbbVie Inc.)、默克公司(Merck &Co.)、艾尔建(Allergan)、Amneal Pharmaceuticals.、Lannett 公司、迈兰製药(Mylan Pharmaceuticals)、辉瑞( Pfizer)、Akorn Pharmaceuticals、Acella Pharmaceuticals、杰罗姆史蒂文斯製药(Jerome Stevens Pharmaceuticals) 和其他知名公司。
  • 该报告的见解将帮助负责人和公司经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球桥本甲状腺炎治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球桥本甲状腺炎治疗药物市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 併购场景

第四章桥本甲状腺炎治疗药物的全球市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章2019-2031年全球桥本甲状腺炎治疗药物市场（依药物类型）

  • 甲状腺荷尔蒙补充疗法
  • 发炎药
  • 抗甲状腺药物
  • 抗促泌素药物
  • β受体阻断剂
  • 钙离子通道阻断剂
  • 其他（补充品等）

第六章全球桥本甲状腺炎治疗药物市场，依给药途径，2019-2031

  • 口服
  • 胃肠外的
  • 局部的

第七章2019-2031年全球桥本甲状腺炎治疗药物市场（按剂型）

  • 药片
  • 胶囊
  • 软凝胶
  • 奶油
  • 其他（药膏/其他）

第8章2019-2031年全球桥本甲状腺炎治疗药物市场（依通路）

  • 医院药房
  • 零售药房
  • 网路药房

第9章2019-2031年全球桥本甲状腺炎治疗药物市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第10章竞争格局

  • AbbVie Inc.
  • Merck & Co.
  • Amneal Pharmaceuticals.
  • Lannett Company
  • Mylan Pharmaceuticals
  • Pfizer
  • Akorn Pharmaceuticals
  • Acella Pharmaceuticals
  • Jerome Stevens Pharmaceuticals
  • Other Prominent Players

第11章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6675

The global Hashimoto's thyroiditis drug market was valued at US$ 2.18 Bn in 2023 and is expected to reach US$ 3.40 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 2.18 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 5.70% 2030/2031 Value Projection: US$ 3.40 Bn
Figure 1. Global Hashimoto's Thyroiditis Drug Market Share (%), by Region, 2023
Global Hashimoto's Thyroiditis Drug Market - IMG1

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is a long-term autoimmune disease in which the thyroid gland is attacked by the body's immune system. Some of the major symptoms include goiter formation in the neck, fatigue, unexplained weight gain, and sensitivity to cold. It is one of the most common causes of hypothyroidism in the U.S., which it affecting about 14 million Americans and costs billions in treatment annually. A variety of drugs are being used for its management, such as levothyroxine, to replace thyroid hormones, corticosteroids to suppress the immune response, and other symptom management drugs. With increasing incidence rates and overall healthcare cost burden, the Hashimoto's thyroiditis drug market is poised to grow significantly in the coming years.

Market Dynamics:

The Hashimoto's thyroiditis drug market is driven by the rising prevalence of autoimmune diseases globally, growing geriatric population, increasing awareness about the condition, and its management. According to an article published in the National Center for Biotechnology Information (NCBI) in 2023, after age six, Hashimoto is the most common cause of hypothyroidism in the U.S. and in those areas of the world where iodine intake is adequate. Globally, the incidence is estimated to be 0.8 per 1,000 per year in men and 3.5 per 1,000 per year in women. However, lack of awareness in developing nations, high costs of biologic drugs, and social stigma continue to restrain the market growth. On the other hand, the development of targeted therapies, combination drug treatments and online disease communities have opened up opportunities for players in this space. The market is witnessing the rising adoption of oral medications over surgical interventions. Players are investing in R&D to develop novel formulations with improved efficacy and safety profiles.

Key Features of the Study:

  • This report provides an in-depth analysis of the global Hashimoto's thyroiditis drug market, and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Hashimoto's thyroiditis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include AbbVie Inc., Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome Stevens Pharmaceuticals, and other prominent players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Hashimoto's thyroiditis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Hashimoto's thyroiditis drug market

Detailed Segmentation:

  • By Drug Type
    • Thyroid hormone replacement therapy
    • Anti-inflammatory drugs
    • Antithyroid medications
    • Anti-cretin medications
    • Beta-blockers
    • Calcium channel blockers
    • Others (Supplements and Others)
  • By Route of Administration
    • Oral
    • Injections
    • Topical
  • By Dosage Form
    • Tablets
    • Capsules
    • Softgels
    • Creams
    • Others (Ointments and Others)
  • By End Users
    • Hospitals
    • Sleep Centers
    • Home Care Settings
    • Diagnostic Laboratories
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Top Companies in the Global Hashimoto's Thyroiditis Drug Market
    • AbbVie Inc.
    • Merck & Co.
    • Allergan
    • Amneal Pharmaceuticals.
    • Lannett Company
    • Mylan Pharmaceuticals
    • Pfizer
    • Akorn Pharmaceuticals
    • Acella Pharmaceuticals
    • Jerome Stevens Pharmaceuticals
    • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Hashimoto's Thyroiditis Drug Market, By Drug Type
    • Global Hashimoto's Thyroiditis Drug Market, By Route of Administration
    • Global Hashimoto's Thyroiditis Drug Market, By Dosage Form
    • Global Hashimoto's Thyroiditis Drug Market, By Distribution Channel
    • Global Hashimoto's Thyroiditis Drug Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Hashimoto's Thyroiditis Drug Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Hashimoto's Thyroiditis Drug Market, By Drug Type, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Thyroid hormone replacement therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Anti-inflammatory drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Antithyroid medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Anti-cretin medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Beta-blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Calcium channel blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Others (Supplements and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

6. Global Hashimoto's Thyroiditis Drug Market, By Route of Administration, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

7. Global Hashimoto's Thyroiditis Drug Market, By Dosage Form, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Tablets
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Capsules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Softgels
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Creams
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Others (Ointments and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

8. Global Hashimoto's Thyroiditis Drug Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

9. Global Hashimoto's Thyroiditis Drug Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020 - 2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

  • AbbVie Inc.
  • Merck & Co.
  • Amneal Pharmaceuticals.
  • Lannett Company
  • Mylan Pharmaceuticals
  • Pfizer
  • Akorn Pharmaceuticals
  • Acella Pharmaceuticals
  • Jerome Stevens Pharmaceuticals
  • Other Prominent Players
  • Analyst Views

11. Section

  • Research Methodology
  • About us